试验观察：PD1/PDL1免疫检查点抑制剂的临床试验概况 - Suppr

Suppr

超能文献

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

作者信息

Tang Jun, Yu Jia Xin, Hubbard-Lucey Vanessa M, Neftelinov Svetoslav T, Hodge Jeffrey P, Lin Yunqing

机构信息

Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

IQVIA, Durham, NC, USA.

出版信息

Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.

DOI:10.1038/nrd.2018.210

PMID:30482962

Abstract

摘要

相似文献

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.

Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.

Nat Rev Drug Discov. 2021 Mar;20(3):168-169. doi: 10.1038/d41573-020-00204-y.

[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].

Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14.

Anti-PD1/PDL1 induced psoriasis.

Curr Probl Cancer. 2017 Nov-Dec;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003. Epub 2017 Oct 18.

New checkpoint inhibitors ride the immunotherapy tsunami.

Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.

Resistance to PD1/PDL1 checkpoint inhibition.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27.

Part I: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051.

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024.

The promise and challenges of immune agonist antibody development in cancer.

Nat Rev Drug Discov. 2018 Jul;17(7):509-527. doi: 10.1038/nrd.2018.75. Epub 2018 Jun 15.

Immune agonist antibodies face critical test.

Nat Rev Drug Discov. 2020 Jan;19(1):3-5. doi: 10.1038/d41573-019-00214-5.

引用本文的文献

CRISPR/Cas9-mediated PD-1 attenuation enhances tumor infiltrating lymphocyte-based adoptive cellular therapy in humanized-PDX model of hepatocellular carcinoma.

Transl Oncol. 2025 Oct;60:102484. doi: 10.1016/j.tranon.2025.102484. Epub 2025 Aug 5.

Polysialic acid is upregulated on activated immune cells and negatively regulates anticancer immune activity.

Front Oncol. 2025 Mar 20;15:1520948. doi: 10.3389/fonc.2025.1520948. eCollection 2025.

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study.

BMJ Open. 2025 Feb 20;15(2):e098062. doi: 10.1136/bmjopen-2024-098062.

Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1.

EXCLI J. 2024 Oct 29;23:1303-1326. doi: 10.17179/excli2024-7783. eCollection 2024.

Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis.

ESC Heart Fail. 2025 Apr;12(2):1237-1245. doi: 10.1002/ehf2.15131. Epub 2024 Oct 31.

Losartan-based nanocomposite hydrogel overcomes chemo-immunotherapy resistance by remodeling tumor mechanical microenvironment.

J Nanobiotechnology. 2024 Oct 30;22(1):667. doi: 10.1186/s12951-024-02871-0.

Single-cell sequencing reveals the immune microenvironment associated with gastric cancer.

Genes Dis. 2024 Jan 26;12(1):101218. doi: 10.1016/j.gendis.2024.101218. eCollection 2025 Jan.

PEDF-Enriched Extracellular Vesicle for Vessel Normalization to Potentiate Immune Checkpoint Blockade Therapy.

Biomater Res. 2024 Oct 1;28:0068. doi: 10.34133/bmr.0068. eCollection 2024.

Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy.

Front Immunol. 2024 Sep 16;15:1456030. doi: 10.3389/fimmu.2024.1456030. eCollection 2024.

The basic biology of NK cells and its application in tumor immunotherapy.

Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024.

本文引用的文献

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

作者信息

Tang Jun, Yu Jia Xin, Hubbard-Lucey Vanessa M, Neftelinov Svetoslav T, Hodge Jeffrey P, Lin Yunqing

机构信息

Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

IQVIA, Durham, NC, USA.

出版信息

Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.

DOI:10.1038/nrd.2018.210

PMID:30482962

Abstract

摘要

相似文献

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.

Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.

Nat Rev Drug Discov. 2021 Mar;20(3):168-169. doi: 10.1038/d41573-020-00204-y.

[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].

Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14.

Anti-PD1/PDL1 induced psoriasis.

Curr Probl Cancer. 2017 Nov-Dec;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003. Epub 2017 Oct 18.

New checkpoint inhibitors ride the immunotherapy tsunami.

Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.

Resistance to PD1/PDL1 checkpoint inhibition.

Cancer Treat Rev. 2017 Jan;52:71-81. doi: 10.1016/j.ctrv.2016.11.007. Epub 2016 Nov 27.

Part I: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016 Jun;8(6):675-6. doi: 10.2217/imt-2016-0051.

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024.

The promise and challenges of immune agonist antibody development in cancer.

Nat Rev Drug Discov. 2018 Jul;17(7):509-527. doi: 10.1038/nrd.2018.75. Epub 2018 Jun 15.

Immune agonist antibodies face critical test.

Nat Rev Drug Discov. 2020 Jan;19(1):3-5. doi: 10.1038/d41573-019-00214-5.

引用本文的文献

CRISPR/Cas9-mediated PD-1 attenuation enhances tumor infiltrating lymphocyte-based adoptive cellular therapy in humanized-PDX model of hepatocellular carcinoma.

Transl Oncol. 2025 Oct;60:102484. doi: 10.1016/j.tranon.2025.102484. Epub 2025 Aug 5.

Polysialic acid is upregulated on activated immune cells and negatively regulates anticancer immune activity.

Front Oncol. 2025 Mar 20;15:1520948. doi: 10.3389/fonc.2025.1520948. eCollection 2025.

BMJ Open. 2025 Feb 20;15(2):e098062. doi: 10.1136/bmjopen-2024-098062.

Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1.

EXCLI J. 2024 Oct 29;23:1303-1326. doi: 10.17179/excli2024-7783. eCollection 2024.

Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis.

ESC Heart Fail. 2025 Apr;12(2):1237-1245. doi: 10.1002/ehf2.15131. Epub 2024 Oct 31.

Losartan-based nanocomposite hydrogel overcomes chemo-immunotherapy resistance by remodeling tumor mechanical microenvironment.

J Nanobiotechnology. 2024 Oct 30;22(1):667. doi: 10.1186/s12951-024-02871-0.

Single-cell sequencing reveals the immune microenvironment associated with gastric cancer.

Genes Dis. 2024 Jan 26;12(1):101218. doi: 10.1016/j.gendis.2024.101218. eCollection 2025 Jan.

PEDF-Enriched Extracellular Vesicle for Vessel Normalization to Potentiate Immune Checkpoint Blockade Therapy.

Biomater Res. 2024 Oct 1;28:0068. doi: 10.34133/bmr.0068. eCollection 2024.

Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy.

Front Immunol. 2024 Sep 16;15:1456030. doi: 10.3389/fimmu.2024.1456030. eCollection 2024.

The basic biology of NK cells and its application in tumor immunotherapy.

Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024.

本文引用的文献

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.